ClinicalTrials.gg
Active, not recruitingNCT06710470Updated Nov 29, 2024

A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

An observational study in Psoriasis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Bristol-Myers Squibb · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
833
Ages
15 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.

Planned enrollment
5th of 14
833 · median 528
Started
2024
with 2 others
Observational
14 of 42
5 open now
Primary completion
2027-01
later than 1 of 13 live
Registered
36th of 42
by date

Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 1 of the 13 other live ones, and was the 36th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 15 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Psoriasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
04

Who can participate

Ages eligible
15 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will include women aged 15 through 50 years with psoriasis who become pregnant (based on their estimated date of conception) from 09-Sep-2022 through 31-Oct-2026 that have been identified in the Optum Research Database (ORD).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maternal age 15 through 50 years at date of conception
  • Start of pregnancy, defined as the estimated date of conception, during the accrual period (09-Sep-2022 through 31-Oct-2026)
  • Continuous medical and pharmacy coverage for a minimum of 6 months prior to and including the estimated date of conception
  • Presence of psoriasis from 12 months prior to the date of conception through the end of pregnancy

Exclusion criteria

Exclusion Criteria:

  • Exposure to any known teratogens from 5 half-lives prior to the estimated date of conception through the end of the relevant exposure window
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
833 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Participants exposed to deucravacitinib for the full pregnancy duration

    Drug: Deucravacitinib

  • Cohort 2

    Participants exposed to deucravacitinib for the first trimester

    Drug: Deucravacitinib

  • Cohort 3

    Participants exposed to deucravacitinib for the first 20 weeks of gestation

    Drug: Deucravacitinib

  • Cohort 4

    Participants exposed to other systemic psoriasis medications for the full pregnancy duration

    Drug: Systemic psoriasis medications

  • Cohort 5

    Participants exposed to other systemic psoriasis medications for the first trimester

    Drug: Systemic psoriasis medications

  • Cohort 6

    Participants exposed to other systemic psoriasis medications for the first 20 weeks of gestation

    Drug: Systemic psoriasis medications

  • Cohort 7

    Participants not exposed to any systemic medications for the full pregnancy duration

    Other: No systemic medications

  • Cohort 8

    Participants not exposed to any systemic medications during the first trimester

    Other: No systemic medications

  • Cohort 9

    Participants not exposed to any systemic medications during the first 20 weeks of gestation

    Other: No systemic medications

Interventions

  • As per product label

  • DrugSystemic psoriasis medications

    As per product label

  • OtherNo systemic medications

    Participants not exposed to any systemic medications

06

What researchers measure

Primary outcomes

  1. Number of infants born with Major Congenital Malformations (MCMs)

    MCMs defined as a structural abnormality with surgical, medical, or cosmetic importance (excluding chromosomal abnormalities or physiological features due to complications of prematurity, such as cryptorchidism, inguinal hernia, or isolated patent ductus arteriosus in infants born less than 37 weeks of gestation)

    Time frame: Up to 12 months after birth or date of health plan disenrollment

Secondary outcomes

  1. Pregnancy outcomes

    Incidence of the following pregnancy outcomes: spontaneous abortion, induced abortion, ectopic pregnancy, stillbirth, pre-eclampsia, eclampsia and gestational diabetes

    Time frame: Up to 9 months or date of health plan disenrollment

  2. Infant outcomes

    Incidence of the following infant outcomes: small for gestational age, large for gestational age, low birthweight, preterm birth, serious or opportunistic infections, postnatal growth deficiency, infant developmental deficiency, neonatal hospitalization, and infant/neonatal/perinatal death

    Time frame: Up to 12 months after birth or date of health plan disenrollment

07

Study locations

1 site
  • Bristol-Meyers Squibb
    Lawrenceville, New Jersey 08648, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Nov 29, 2024
StartActual
Aug 2, 2024
Primary completionEst.
Jan 31, 2027
CompletionEst.
Feb 28, 2029
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06710470
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Aug 2, 2024
Primary completion
Jan 31, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Nov 29, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion